8-K/A: Windtree Therapeutics Finalizes Employment Agreement with New CFO

Windtree Therapeutics has finalized the employment agreement with its newly appointed CFO, Jamie McAndrew, detailing her compensation and termination benefits.

Summary

• Windtree Therapeutics has amended its previous 8-K filing to include the finalized employment agreement with Jamie McAndrew, the new Senior Vice President, Chief Financial Officer.
• Ms. McAndrew's annual base salary is set at $370,000, with eligibility for a year-end bonus targeted at 40% of her base salary, payable in cash or equity.
• The agreement includes a 12-month post-employment non-competition clause, along with confidentiality and intellectual property assignment obligations.
• Upon termination without cause or for good reason, Ms. McAndrew is entitled to a pro-rata bonus, severance pay equal to 12 months of her base salary, and continued medical benefits under COBRA.
• In the event of a change of control, Ms. McAndrew will receive 1.5 times her base salary plus target bonus as severance, and all equity awards will fully vest.
• The agreement also includes an automatic extension until the second anniversary of a change of control if Ms. McAndrew remains CFO.

Sentiment

Score: 7

Explanation: The document is a routine update on an employment agreement, which is generally positive for stability. The terms are standard and do not indicate any significant issues.

Positives

• The employment agreement provides clear terms for Ms. McAndrew's compensation and benefits.
• The agreement includes standard protections for the company, such as non-competition and confidentiality clauses.
• The severance package provides financial security for Ms. McAndrew in the event of termination without cause or a change of control.
• The acceleration of equity vesting upon a change of control aligns Ms. McAndrew's interests with shareholders.

Negatives

• The agreement includes potentially significant severance costs for the company in the event of termination without cause or a change of control.
• The 18-month continuation of benefits after a change of control could be a substantial expense for the company.

Risks

• The company may incur significant costs if Ms. McAndrew's employment is terminated without cause or if there is a change of control.
• The non-competition agreement could limit Ms. McAndrew's future employment options.

Future Outlook

The employment agreement is effective until terminated and includes a 12-month post-employment non-competition agreement. The agreement also includes an automatic extension until the second anniversary of a change of control if Ms. McAndrew remains CFO.

Management Comments

• The Board approved an employment agreement with Ms. McAndrew setting forth the compensation arrangement for this position.

Industry Context

The finalization of the CFO's employment agreement is a standard corporate practice, ensuring clarity and stability in the company's financial leadership. The terms of the agreement, including compensation and severance, are likely benchmarked against industry standards for similar roles.

Comparison to Industry Standards

• The base salary of $370,000 for a CFO at a company of Windtree's size is within the typical range for the pharmaceutical industry.
• The 40% target bonus is also a common incentive structure for executive roles.
• The severance package, including 12 months of base salary upon termination without cause, is a standard practice to protect executives.
• The change of control provisions, including accelerated vesting of equity and a severance payment of 1.5 times base salary plus target bonus, are also common in executive employment agreements.
• Companies such as Aclaris Therapeutics and BioCryst Pharmaceuticals, which are similar in size and stage to Windtree, often have similar compensation and severance structures for their CFOs.

Management Changes

Stakeholder Impact

• Shareholders will gain clarity on the compensation structure for the CFO.
• Employees will see stability in the financial leadership of the company.
• The agreement provides financial security for the CFO.

Next Steps

• The full employment agreement will be filed as an exhibit to the company's Annual Report on Form 10-K for the year ended December 31, 2024.

Key Dates

Keywords

employment agreement, CFO, compensation, severance, change of control, non-competition, equity, bonus, Windtree Therapeutics